For anyone in Tsuha looking to source CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. The core insight for Tsuha researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Tsuha researcher needs before placing a first order.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Tsuha comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
Before looking at individual vendors, understand what genuine quality documentation contains — so you can tell whether a COA is complete and credible. The HPLC analytical chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be 98% or higher. Negative indicators in CJC-1295 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. The lyophilised (freeze-dried) form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Tsuha
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the safety data available for CJC-1295 is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and used within 30 days; reconstitute only with sterile bacteriostatic water. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. Researchers combining CJC-1295 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
